Prognosis and tumor-infiltrating lymphocytes (TILs) in estrogen receptor (ER)-low metastatic breast cancer (MBC): Analysis from a large multi-institutional cohort and the TONIC phase II trial with nivolumab.

Federica Miglietta, Maria Vittoria Dieci, Angelo Paolo Dei Tos et al.|Journal of Clinical Oncology|2024

Cited by 1